Myelodysplastic Syndromes News and Research

RSS

Study provides insight into what causes therapy failure in patients with myelodysplastic syndromes

Researchers from The University of Texas MD Anderson Cancer Center discovered that treatment resistance in patients with myelodysplastic syndromes (MDS) is caused by two distinct classes of stem cells and identified possible therapeutic approaches that target these cells.

3 Mar 2022

Optical genome mapping holds potential to become an important component of leukemia diagnostics

Optical genome mapping involves the extraction of very long DNA molecules, for example routinely collected blood samples or bone marrow material from patients.

17 Feb 2022

Defective gene in blood cancers could be treated with already available drugs

A defective gene, normally found in blood cancers, could be treated with drugs already available for cancers with similar gene defects, scientists at Queen’s University Belfast and the University of Birmingham have revealed.

13 Jan 2022

Novel therapy found to be safe and well-tolerated in patients with bone marrow cancer

Mount Sinai physician-scientists have found that a novel therapy for the bone marrow cancer myelofibrosis is safe and well-tolerated and is associated with modest improvements in patients in a Phase 1b clinical trial.

12 Dec 2021

Investigational combo therapy shows promise in treating TP53 mutant MDS and AML patients

Myelodysplastic Syndromes (MDS) and acute myeloid leukemia (AML) are rare hematologic malignancies of the bone marrow.

21 Jan 2021

Beat AML trial achieves primary endpoint

Patients participating in The Leukemia & Lymphoma Society's (LLS) groundbreaking precision medicine Beat AML Master Clinical Trial had superior outcomes compared to acute myeloid leukemia (AML) patients who opted for standard chemotherapy treatment, according to findings published today in the prestigious Nature Medicine journal.

28 Oct 2020

MD Anderson and Astex Pharmaceuticals partner to accelerate clinical evaluation of leukemia therapies

The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co. Ltd., based in Tokyo, Japan, today announce a strategic collaboration agreement aimed at accelerating the clinical evaluation of Astex's pipeline of products for patients with certain types of leukemia, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML).

8 Sep 2020

Study identifies impact of gene mutations on severity of myelodysplastic syndrome

The Myelodysplastic Syndromes Group of Josep Carreras Leukaemia Research Institute, led by Dr. Francesc Solé, has participated in the first international study that confirms that having two mutated copies of the TP53 gene, as opposed to a single mutated copy, is associated with a worse prognosis in patients diagnosed with myelodysplastic syndrome (MDS).

4 Aug 2020

Research reveals the molecular landscape of myelodysplastic/myeloproliferative neoplasms

Myelodysplastic/myeloproliferative neoplasms (MDS/MPN) is a group of rare malignancies with overlapping features from myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN), that include a variety of diseases depending on their phenotype (hematological and morphological characteristics).

1 Jul 2020

Researchers receive innovative grants to understand the biological underpinnings of blood cancers

Seeking to ignite the next major breakthroughs to treat blood cancers, The Leukemia & Lymphoma Society (LLS), The Mark Foundation, and The Paul G. Allen Frontiers Group today announced more than $6.75 million awarded to nine of the most exceptional scientists in the field.

1 Jul 2020

Newer treatment approaches may reduce risk of therapy-related hematologic cancers

While breakthrough treatments have emerged for several cancers over the last two decades, driving striking improvements in survival and other clinical outcomes, too little is known about the risk of therapy-related hematologic cancers following targeted and immunotherapeutic approaches.

29 May 2020

Takeda to present oncology pipeline data at upcoming virtual scientific congresses

Takeda Pharmaceutical Company Limited today announced that the company will present data from its expanding oncology pipeline and established product portfolio at two upcoming virtual scientific congresses: the 56th Annual Meeting of the American Society of Clinical Oncology, May 29-31 and the 25th Virtual Congress of the European Hematology Association, June 11-14.

18 May 2020

Kurome secures license to develop novel therapies for chemo-resistant cancer

Seed investor CincyTech announced the formation of Kurome Therapeutics ("Kurome"), a preclinical stage company developing novel therapies targeting cancer cells' adaptive resistance mechanisms beginning with hematopoietic, or blood cell, cancers.

29 Apr 2020

New clinical trial uses universal natural killer cell approach to treat acute myeloid leukemia

A new, phase I clinical trial offered The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute will treat patients with relapsed or refractory acute myeloid leukemia using a novel universal natural killer cell approach.

27 Feb 2020

New research could lead to 'breakthrough' for myelodysplastic syndrome

Korean researchers have observed cup-shaped red blood cells in the peripheral blood of a patient with myelodysplastic syndrome.

From Tomocube Inc. 30 Jan 2020

Rutgers researchers identify small mutations for AML and MDS through deep DNA sequencing

Deep DNA sequencing analysis conducted by Rutgers Cancer Institute of New Jersey investigators examining genomic differences within tumors for prediction of disease relapse in certain hematologic malignancies has identified small mutations.

9 Dec 2019

Venetoclax in combination with azacytidine aids therapy for myelodysplastic syndromes

A new study by Yale Cancer Center and Smilow Cancer Hospital researchers suggests that the drug venetoclax aids therapy for relapsed/refractory myelodysplastic syndromes, especially when paired with azacytidine.

9 Dec 2019

New guide for genomic diagnosis of myelodysplastic syndromes and chronic myelomonocytic leukemia published

In Spain, a workgroup of more than 400 researchers, the Spanish Group of Myelodysplastic Syndromes, meets twice a year to present projects and undertake collaborations that improve their work in the fight against Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia, two types of blood cancers.

4 Nov 2019

Combination of two drugs disrupts cancer cells' ability to survive DNA damage, study finds

In continuing efforts to find novel ways to kill cancer cells, researchers at the University of Maryland School of Medicine have identified a new pathway that leads to the destruction of cancer cells.

14 Oct 2019

Researchers discover metabolic vulnerability in cancer cells with mutated spliceosomes

A research team from the Johns Hopkins Kimmel Cancer Center reports it has discovered a metabolic vulnerability in multiple types of cancer cells that bear a common genetic mutation affecting cellular machines called spliceosomes.

From Johns Hopkins Medicine 3 Oct 2019